Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 4 (2007), Issue 4 (April)

1. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study.
   Int J Cancer, 120(10): 2214-20. [Abstract] [Full-text]
2. Targeting novel and established therapies for non-small cell lung cancer.
   Cancer Lett, 250(1): 9-16. [Abstract] [Full-text]
3. Registration of DRRs and portal images for verification of stereotactic body radiotherapy: a feasibility study in lung cancer treatment.
   Phys Med Biol, 52(8): 2157-70. [Abstract] [Full-text]
4. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.
   Clin Cancer Res, 13(7): 2281-9. [Abstract] [Full-text]
5. 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study.
   Clin Cancer Res, 13(7): 1995-2004. [Abstract] [Full-text]
6. The potential of antiangiogenic therapy in non-small cell lung cancer.
   Clin Cancer Res, 13(7): 1961-70. [Abstract] [Full-text]
7. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.
   Trends Mol Med, 13(4): 150-7. [Abstract] [Full-text]
8. Metagene projection for cross-platform, cross-species characterization of global transcriptional states.
   Proc Natl Acad Sci U S A, 104(14): 5959-64. [Abstract] [Full-text]
9. Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial.
   Br J Cancer, 96(7): 1052-6. [Abstract] [Full-text]
10. Inactivation of LLC1 gene in nonsmall cell lung cancer.
    Int J Cancer, 120(11): 2353-8. [Abstract] [Full-text]
11. Endobronchial ultrasound-guided fine-needle aspiration and liquid-based thin-layer cytology.
    J Clin Pathol, 60(4): 388-91. [Abstract] [Full-text]
12. Finding the limit between station 2 and station 4 during right-sided thoracotomy.
    Thorac Cardiovasc Surg, 55(3): 203-4. [Abstract] [Full-text]
13. Bilateral surgical resection in pulmonary epitheloid hemangioendothelioma.
    Thorac Cardiovasc Surg, 55(3): 199-200. [Abstract] [Full-text]
14. Esophageal stent placement for the palliation of dysphagia in lung cancer.
    Thorac Cardiovasc Surg, 55(3): 196-8. [Abstract] [Full-text]
15. Primary malignant fibrous histiocytoma of the lung.
    Thorac Cardiovasc Surg, 55(3): 186-9. [Abstract] [Full-text]
16. Isolated lung perfusion with Paclitaxel and docetaxel: comparison of the early effects on pulmonary physiology.
    Thorac Cardiovasc Surg, 55(3): 177-9. [Abstract] [Full-text]
17. Transcervical extended mediastinal lymphadenectomy: results of staging in two hundred fifty-six patients with non-small cell lung cancer.
    J Thorac Oncol, 2(4): 370-2. [Abstract] [Full-text]
18. Video-assisted mediastinoscopic lymphadenectomy (VAMLA).
    J Thorac Oncol, 2(4): 367-9. [Abstract] [Full-text]
19. Remediastinoscopy.
    J Thorac Oncol, 2(4): 365-6. [Abstract] [Full-text]
20. Mediastinoscopic ultrasonography.
    J Thorac Oncol, 2(4): 362-4. [Abstract] [Full-text]
21. European trends in preoperative and intraoperative nodal staging: ESTS guidelines.
    J Thorac Oncol, 2(4): 357-61. [Abstract] [Full-text]
22. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
    J Thorac Oncol, 2(4): 348-54. [Abstract] [Full-text]
23. Pulmonary blastoma with renal metastasis responds to sorafenib.
    J Thorac Oncol, 2(4): 344-7. [Abstract] [Full-text]
24. A translational view of the molecular pathogenesis of lung cancer.
    J Thorac Oncol, 2(4): 327-43. [Abstract] [Full-text]
25. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
    J Thorac Oncol, 2(4): 321-4. [Abstract] [Full-text]
26. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer.
    J Thorac Oncol, 2(4): 312-6. [Abstract] [Full-text]
27. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
    J Thorac Oncol, 2(4): 306-11. [Abstract] [Full-text]
28. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    J Thorac Oncol, 2(4): 299-305. [Abstract] [Full-text]
29. Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients.
    J Thorac Oncol, 2(4): 293-8. [Abstract] [Full-text]
30. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    J Thorac Oncol, 2(4): 287-92. [Abstract] [Full-text]
31. Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases.
    J Thorac Oncol, 2(4): 282-6. [Abstract] [Full-text]
32. Does intensive follow-up alter outcome in patients with advanced lung cancer?
    J Thorac Oncol, 2(4): 273-81. [Abstract] [Full-text]
33. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy.
    J Thorac Oncol, 2(4): 268-72. [Abstract] [Full-text]
34. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
    Cancer Res, 67(7): 3461-7. [Abstract] [Full-text]
35. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
    Cancer Res, 67(7): 3329-36. [Abstract] [Full-text]
36. p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers.
    Cancer Res, 67(7): 3162-70. [Abstract] [Full-text]
37. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice.
    Cancer Res, 67(7): 3475-82. [Abstract] [Full-text]
38. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.
    Blood, 109(8): 3603-6. [Abstract] [Full-text]
39. Automated volumetry of solid pulmonary nodules in a phantom: accuracy across different CT scanner technologies.
    Invest Radiol, 42(5): 297-302. [Abstract] [Full-text]
40. Diffuse pulmonary meningotheliomatosis.
    Am J Surg Pathol, 31(4): 624-31. [Abstract] [Full-text]
41. Desmoplastic small round cell tumor of the kidney in childhood.
    Am J Surg Pathol, 31(4): 576-84. [Abstract] [Full-text]
42. Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation.
    Am J Surg Pathol, 31(4): 562-8. [Abstract] [Full-text]
43. Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis?
    Int J Gynecol Pathol, 26(2): 134-40. [Abstract] [Full-text]
44. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Exp Cell Res, 313(7): 1361-72. [Abstract] [Full-text]
45. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
    J Clin Oncol, 25(11): 1377-82. [Abstract] [Full-text]
46. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.
    Cancer Epidemiol Biomarkers Prev, 16(4): 823-8. [Abstract] [Full-text]
47. On the dose to a moving target while employing different IMRT delivery mechanisms.
    Radiother Oncol, 83(1): 49-56. [Abstract] [Full-text]
48. Retrospective attenuation correction of PET data for radiotherapy planning using a free breathing CT.
    Radiother Oncol, 83(1): 42-8. [Abstract] [Full-text]
49. Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy (IGRT) of pulmonary tumors.
    Radiother Oncol, 83(1): 57-64. [Abstract] [Full-text]
50. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
    Vaccine, 25(17): 3338-46. [Abstract] [Full-text]
51. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis.
    Hum Mutat, 28(5): 431-40. [Abstract] [Full-text]
52. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis.
    Brain Behav Immun, 21(4): 395-408. [Abstract] [Full-text]
53. Prolonged survival after resection and radiotherapy for solitary brain metastases from non-small-cell lung cancer.
    Australas Radiol, 51(2): 186-9. [Abstract] [Full-text]
54. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Mol Cancer Res, 5(4): 393-401. [Abstract] [Full-text]
55. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.
    Mol Cancer Res, 5(4): 331-9. [Abstract] [Full-text]
56. Adenocarcinoma of the lung presenting as a mycetoma with an air crescent sign.
    Chest, 131(4): 1239-42. [Abstract] [Full-text]
57. Catheter-tract metastases associated with chronic indwelling pleural catheters.
    Chest, 131(4): 1232-4. [Abstract] [Full-text]
58. Ability of low-dose helical CT to distinguish between benign and malignant noncalcified lung nodules.
    Chest, 131(4): 1028-34. [Abstract] [Full-text]
59. Declining incidence rate of lung adenocarcinoma in the United States.
    Chest, 131(4): 1000-5. [Abstract] [Full-text]
60. Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer.
    Chest, 131(4): 993-9. [Abstract] [Full-text]
61. Decrease in risk of lung cancer death in Japanese men after smoking cessation by age at quitting: pooled analysis of three large-scale cohort studies.
    Cancer Sci, 98(4): 584-9. [Abstract] [Full-text]
62. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway.
    Cancer Sci, 98(4): 506-11. [Abstract] [Full-text]
63. Flavanone and 2'-OH flavanone inhibit metastasis of lung cancer cells via down-regulation of proteinases activities and MAPK pathway.
    Chem Biol Interact, 167(3): 193-206. [Abstract] [Full-text]
64. Synthetic lethal screen identification of chemosensitizer loci in cancer cells.
    Nature, 446(7137): 815-9. [Abstract] [Full-text]
65. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.
    Nature, 446(7137): 765-70. [Abstract] [Full-text]
66. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Pharmacogenet Genomics, 17(5): 313-9. [Abstract] [Full-text]
67. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
    Expert Rev Anticancer Ther, 7(4): 545-9. [Abstract] [Full-text]
68. Is 18F FDG PET-CT cost effective in lung cancer?
    Expert Rev Anticancer Ther, 7(4): 471-6. [Abstract] [Full-text]
69. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.
    Expert Rev Anticancer Ther, 7(4): 415-22. [Abstract] [Full-text]
70. Comparison of two indices of exposure to polycyclic aromatic hydrocarbons in a retrospective aluminium smelter cohort.
    Occup Environ Med, 64(4): 273-8. [Abstract] [Full-text]
71. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
    Mol Cancer Ther, 6(4): 1440-9. [Abstract] [Full-text]
72. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
    Mol Cancer Ther, 6(4): 1223-9. [Abstract] [Full-text]
73. Alveolar type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in vitro.
    Am J Respir Cell Mol Biol, 36(5): 534-40. [Abstract] [Full-text]
74. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
    Am J Med Sci, 333(4): 221-5. [Abstract] [Full-text]
75. Automated detection of small pulmonary nodules in whole lung CT scans.
    Acad Radiol, 14(5): 579-93. [Abstract] [Full-text]
76. Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats.
    Clin Oncol (R Coll Radiol), 19(4): 260-4. [Abstract] [Full-text]
77. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Diagn Cytopathol, 35(5): 257-62. [Abstract] [Full-text]
78. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum.
    Br J Cancer, 96(8): 1278-83. [Abstract] [Full-text]
79. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
    Br J Cancer, 96(8): 1191-6. [Abstract] [Full-text]
80. A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity.
    Hum Pathol, 38(5): 702-9. [Abstract] [Full-text]
81. Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma.
    Int J Cancer, 120(12): 2643-9. [Abstract] [Full-text]
82. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung.
    Int J Cancer, 120(12): 2538-44. [Abstract] [Full-text]
83. Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk.
    Int J Cancer, 120(12): 2687-95. [Abstract] [Full-text]
84. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion.
    Cancer Res, 67(8): 3936-44. [Abstract] [Full-text]
85. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.
    Cancer Res, 67(8): 3878-87. [Abstract] [Full-text]
86. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
    Cancer Res, 67(8): 3529-34. [Abstract] [Full-text]
87. Lung metastasis genes couple breast tumor size and metastatic spread.
    Proc Natl Acad Sci U S A, 104(16): 6740-5. [Abstract] [Full-text]
88. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling.
    Lab Invest, 87(5): 456-65. [Abstract] [Full-text]
89. CT-guided radiofrequency ablation for lung cancer.
    Int J Clin Oncol, 12(2): 71-8. [Abstract] [Full-text]
90. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    J Clin Oncol, 25(12): 1553-61. [Abstract] [Full-text]
91. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    J Clin Oncol, 25(12): 1545-52. [Abstract] [Full-text]
92. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
    J Clin Oncol, 25(12): 1476-81. [Abstract] [Full-text]
93. A case of pulmonary type of ovarian small cell carcinoma.
    J Obstet Gynaecol Res, 33(2): 203-6. [Abstract] [Full-text]
94. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
    J Neurosci Res, 85(6): 1347-57. [Abstract] [Full-text]
95. Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors.
    Mod Pathol, 20(5): 514-21. [Abstract] [Full-text]
96. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.
    Cell Death Differ, 14(5): 952-62. [Abstract] [Full-text]
97. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells.
    Oncogene, 26(18): 2658-66. [Abstract] [Full-text]
98. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Oncogene, 26(18): 2621-34. [Abstract] [Full-text]
99. Bilateral high-level percutaneous cervical cordotomy in cancer pain due to lung cancer: a case report.
    Surg Neurol, 67(5): 504-7. [Abstract] [Full-text]
100. Numerical calculations of single-cell electroporation with an electrolyte-filled capillary.
     Biophys J, 92(10): 3696-705. [Abstract] [Full-text]
101. Angiogenesis inhibitors in the treatment of lung cancer.
     Crit Rev Oncol Hematol, 62(2): 93-104. [Abstract] [Full-text]
102. Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: a population-based study in the Netherlands.
     Crit Rev Oncol Hematol, 62(2): 172-8. [Abstract] [Full-text]
103. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study.
     Environ Health Perspect, 115(4): 579-85. [Abstract] [Full-text]
104. Multiprojection correlation imaging for improved detection of pulmonary nodules.
     AJR Am J Roentgenol, 188(5): 1239-45. [Abstract] [Full-text]
105. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications.
     AJR Am J Roentgenol, 188(5): 1223-31. [Abstract] [Full-text]
106. Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression.
     Clin Imaging, 31(3): 165-77. [Abstract] [Full-text]
107. Feasibility of image registration and intensity-modulated radiotherapy planning with hyperpolarized helium-3 magnetic resonance imaging for non-small-cell lung cancer.
     Int J Radiat Oncol Biol Phys, 68(1): 273-81. [Abstract] [Full-text]
108. In vivo observation of pulmonary micrometastasis of colon cancer in normal rats.
     Microvasc Res, 73(3): 206-13. [Abstract] [Full-text]
109. Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells.
     Eur J Cancer, 43(7): 1214-24. [Abstract] [Full-text]
110. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer.
     Int J Radiat Oncol Biol Phys, 68(1): 103-10. [Abstract] [Full-text]
111. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
     Lung Cancer, 56(2): 229-34. [Abstract] [Full-text]
112. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
     Lung Cancer, 56(2): 247-54. [Abstract] [Full-text]
113. Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position.
     Int J Radiat Oncol Biol Phys, 68(1): 243-52. [Abstract] [Full-text]
114. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
     Int J Radiat Oncol Biol Phys, 68(1): 94-102. [Abstract] [Full-text]
115. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population.
     Lung Cancer, 56(2): 153-60. [Abstract] [Full-text]
116. Low-dose CT: a useful and accessible tool for the early diagnosis of lung cancer in selected populations.
     Lung Cancer, 56(2): 217-21. [Abstract] [Full-text]
117. Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase II trial.
     Lung Cancer, 56(2): 263-71. [Abstract] [Full-text]
118. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.
     Int J Radiat Oncol Biol Phys, 68(1): 111-8. [Abstract] [Full-text]
119. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
     Lung Cancer, 56(2): 255-62. [Abstract] [Full-text]
120. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers.
     Lung Cancer, 56(2): 161-6. [Abstract] [Full-text]
121. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey.
     Lung Cancer, 56(2): 235-45. [Abstract] [Full-text]
122. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
     Lung Cancer, 56(2): 289-94. [Abstract] [Full-text]
123. CT findings of early-stage small cell lung cancer in a low-dose CT screening programme.
     Lung Cancer, 56(2): 207-15. [Abstract] [Full-text]
124. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer.
     Lung Cancer, 56(2): 175-84. [Abstract] [Full-text]
125. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening.
     Lung Cancer, 56(2): 193-9. [Abstract] [Full-text]
126. Surgical management of lung cancer invading the aorta or the superior vena cava.
     Lung Cancer, 56(2): 223-7. [Abstract] [Full-text]
127. Virtual bronchoscopic navigation system shortens the examination time--feasibility study of virtual bronchoscopic navigation system.
     Lung Cancer, 56(2): 201-6. [Abstract] [Full-text]
128. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
     Lung Cancer, 56(2): 281-8. [Abstract] [Full-text]
129. An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran.
     Lung Cancer, 56(2): 145-51. [Abstract] [Full-text]
130. Differential expression profile of MAGE family in non-small-cell lung cancer.
     Lung Cancer, 56(2): 185-92. [Abstract] [Full-text]
131. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer.
     Lung Cancer, 56(2): 273-80. [Abstract] [Full-text]
132. Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells.
     Lung Cancer, 56(2): 167-74. [Abstract] [Full-text]
133. In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
     Food Chem Toxicol, 45(7): 1194-201. [Abstract] [Full-text]
134. Adjuvant chemotherapy for non-small cell lung cancer.
     J Thorac Oncol, 2(5): S7-11. [Abstract] [Full-text]
135. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.
     J Thorac Oncol, 2(5): S27-30. [Abstract] [Full-text]
136. Hospital volume and late survival after cancer surgery.
     Ann Surg, 245(5): 777-83. [Abstract] [Full-text]
137. Pulmonary nodules: sensitivity of maximum intensity projection versus that of volume rendering of 3D multidetector CT data.
     Radiology, 243(2): 561-9. [Abstract] [Full-text]
138. Lung carcinoma: diffusion-weighted mr imaging--preliminary evaluation with apparent diffusion coefficient.
     Radiology, 243(2): 570-7. [Abstract] [Full-text]
139. Microscopic pulmonary neoplastic emboli: report of a case with respiratory failure but normal imaging.
     Prim Care Respir J, 16(2): 115-7. [Abstract] [Full-text]
140. Suspected lung cancer: its initial management and staging.
     Prim Care Respir J, 16(2): 106-11. [Abstract] [Full-text]
141. Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.
     Am J Surg Pathol, 31(5): 737-43. [Abstract] [Full-text]
142. Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
     Onkologie, 30(5): 260-4. [Abstract] [Full-text]
143. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man.
     Onkologie, 30(5): 253-5. [Abstract] [Full-text]
144. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
     J Med Chem, 50(9): 2249-53. [Abstract] [Full-text]
145. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells.
     Mol Pharmacol, 71(5): 1381-8. [Abstract] [Full-text]
146. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells.
     Carcinogenesis, 28(5): 1058-66. [Abstract] [Full-text]
147. Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
     Carcinogenesis, 28(5): 957-61. [Abstract] [Full-text]
148. Prolonged survival in a patient with recurrent pulmonary metastases secondary to mucinous cystadenocarcinoma of the appendix with pseudomyxomatous peritonei.
     Ann Thorac Surg, 83(5): 1893-4. [Abstract] [Full-text]
149. Association between surgeon and hospital volume and in-hospital fatalities after lung cancer resections: the experience of an Asian country.
     Ann Thorac Surg, 83(5): 1837-43. [Abstract] [Full-text]
150. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting survival.
     Ann Thorac Surg, 83(5): 1831-6. [Abstract] [Full-text]
151. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer.
     Ann Thorac Surg, 83(5): 1826-9; discussion 1829-30. [Abstract] [Full-text]
152. Stereotactic radiosurgery for the treatment of lung neoplasm: initial experience.
     Ann Thorac Surg, 83(5): 1820-4; discussion 1824-5. [Abstract] [Full-text]
153. Intrapulmonary solitary fibrous tumor diagnosed by immunohistochemical and genetic approaches: report of a case.
     Surg Today, 37(5): 423-5. [Abstract] [Full-text]
154. Invasive lymphangioma of the lung manifesting as a large pulmonary mass with hemoptysis: report of a case.
     Surg Today, 37(5): 418-22. [Abstract] [Full-text]
155. Hereditary factors in multiple primary malignancies associated with lung cancer.
     Surg Today, 37(5): 375-8. [Abstract] [Full-text]
156. Laparotomy for acute complications of gastrointestinal metastases from lung cancer: is it a worthwhile or futile effort?
     Surg Today, 37(5): 370-4. [Abstract] [Full-text]
157. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management.
     J Thorac Cardiovasc Surg, 133(5): 1193-200. [Abstract] [Full-text]
158. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.
     J Thorac Cardiovasc Surg, 133(5): 1179-85. [Abstract] [Full-text]
159. Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer.
     J Magn Reson Imaging, 25(5): 992-9. [Abstract] [Full-text]
160. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
     Mass Spectrom Rev, 26(3): 451-66. [Abstract] [Full-text]
161. Intrapulmonary lymph nodes in South African miners--an autopsy survey.
     Am J Ind Med, 50(4): 261-4. [Abstract] [Full-text]
162. Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection.
     Thorax, 62(5): 391-5. [Abstract] [Full-text]
163. Previous tumour as a prognostic factor in stage I non-small cell lung cancer.
     Thorax, 62(5): 386-90. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.